PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Medical - Devices

Healthcare
$25.18 +0.89%

+$0.19 today

Market cap
$1.45B
Beta
0.85
P/E (TTM)
-11.6
EPS (TTM)
-$1.81
52W Low $19.35High $62.17

Volume 2.05M

Average 1.46M

PRCT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

PROCEPT BioRobotics CorporationNASDAQ: PRCT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 64.9%

Gross margin was 64.9% in Q1 FY2026, up 1.0 pp from a year earlier. On a trailing-twelve-month basis it was 63.0%, up 0.3 pp year over year. Over 3 fiscal years it widened by 14.3 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
64.9%+4.3 pp QoQ
Last fiscal yearDec 2025
63.7%+2.6 pp YoY
LTMMar 2026
63.0%+0.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.0 pp——
1 year+2.6 pp——
3 years+14.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
63.7%
Year-over-year change
+2.6pp

Gross Margin vs competitors

How PRCT compares with its peers on the latest reported figures

  • PRCT's LTM Mar 2026 gross margin of 63.0% is the highest of the 5 companies compared; the peer median is 45.9%.
  • Its year-over-year change of +0.3 pp is the lowest of 3, against a peer median of +6.1 pp.
  • Over three fiscal years its change of +14.3 pp compares with a peer median of -1.4 pp.
PRCT Competitors Peer median
Gross Margin for PRCT and competitors
Company Period LTM level YoY 3-year change
PRCTPROCEPT BioRobotics CorporationLTM Mar 202663.0% +0.3 pp+14.3 pp
CLPTClearPoint Neuro, Inc.LTM Mar 202661.8% +0.6 pp-4.5 pp
SSIISS Innovations International, Inc.LTM Mar 202648.4% +11.6 pp+12.4 pp
FOCLEDAP TMS S.A. American Depositary SharesLTM Mar 202643.4% —-1.4 pp
MBOTMicrobot Medical Inc.LTM Mar 2026-9.5% ——
Peer median (excluding PRCT) 45.9%+6.1 pp-1.4 pp

Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.47M75.01M136.19M224.5M308.05M
Cost of Revenue18.61M37.93M65.14M87.4M111.83M
Gross Profit15.87M37.09M71.05M137.1M196.23M
Gross Margin46.0%49.4%52.2%61.1%63.7%
Research & Development18.99M28.98M48.45M62.3M71.28M
Selling, General & Admin51.04M88.83M131.77M171.42M228.81M
Operating Expenses70.03M117.81M180.22M233.71M300.09M
Depreciation & Amortization3.32M2.84M3.81M5.23M6.39M
EBITDA(50.72M)(79.13M)(98.1M)(82M)(85.41M)
EBITDA Margin-147.1%-105.5%-72.0%-36.5%-27.7%
Operating Income(54.16M)(80.72M)(109.17M)(96.61M)(103.86M)
Operating Margin-157.1%-107.6%-80.2%-43.0%-33.7%
Interest Income76K2.5M7.55M10.9M12.22M
Interest Expense5.81M5.18M4M4.18M3.59M
Other Income / Expenses(5.69M)(6.43M)3.27M5.2M8.48M
Income Before Tax(59.85M)(87.15M)(105.9M)(91.41M)(95.38M)
Pre-Tax Margin-173.6%-116.2%-77.8%-40.7%-31.0%
Income Tax Expense0000190K
Net Income(59.85M)(87.15M)(105.9M)(91.41M)(95.57M)
Net Margin-173.6%-116.2%-77.8%-40.7%-31.0%
EPS (Basic)(1.37)(1.96)(2.24)(1.75)(1.72)
EPS (Diluted)(1.37)(1.96)(2.24)(1.75)(1.72)
Weighted Avg Shares43.7M44.4M47.26M52.13M55.54M
Weighted Avg Shares (Diluted)43.7M44.4M47.26M52.13M55.54M

PROCEPT BioRobotics Corporation

NASDAQ:PRCT

Intrinsic Alpha fair value

Locked

Current Price

$25.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.